Solid Biosciences Inc. filings document regulatory disclosures for a Nasdaq-listed precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its SEC records include Form 8-K reports on operating and financial results, Regulation FD presentations, clinical updates for SGT-003 and the INSPIRE DUCHENNE trial, material agreements, and capital-structure matters.
Proxy filings describe annual stockholder meeting proposals, board classification matters, advisory votes, executive compensation, and equity awards. The filing record also identifies the company’s common stock as listed on The Nasdaq Global Select Market under the SLDB symbol.
Solid Biosciences Inc. reported that Chief Regulatory Officer Jessie Hanrahan acquired 54,925 restricted stock units (RSUs) as a compensation grant. Each RSU represents a contingent right to receive one share of Solid Biosciences common stock.
These RSUs relate to performance stock units (PSUs) granted on June 11, 2024. The PSUs vest in four 25% tranches upon achieving independent, Board‑determined performance milestones that are non‑market and non‑financial. The Board determined that the second performance milestone was met on January 29, 2026, and the related shares will vest subject to continued service through an evaluation date anticipated in the first quarter of 2027.
Solid Biosciences Inc. will hold a virtual 2026 Annual Meeting of Stockholders on June 10, 2026 to vote on director elections, auditor ratification and corporate governance proposals. The Board requests votes to elect three Class II directors—Clare Kahn, Adam Stone and Lynne Sullivan—and to ratify the advisory appointment of Ilan Ganot as a Class I director. The Board also asks stockholders to ratify PricewaterhouseCoopers LLP as the independent registered public accounting firm and to approve an amendment to the Certificate of Incorporation to increase authorized common shares from 240,000,000 to 480,000,000. The Board has set the record date as April 16, 2026 and recommends voting "FOR" each proposal.
Solid Biosciences Inc. reported a technical change to its Board structure. Effective at 4:00 p.m. Eastern Time on April 10, 2026, director Ilan Ganot resigned from the Class III director group and was immediately reappointed as a Class I director.
This adjustment sets both Class I and Class III at three directors each and is described as being for the sole purpose of achieving an equal balance among the Board’s three classes. Mr. Ganot’s new Class I term will run until the 2028 Annual Meeting of Stockholders.
The company plans to ask stockholders at the 2026 Annual Meeting to ratify, on an advisory basis, Mr. Ganot’s appointment as a Class I Director, reflecting its corporate governance focus. His compensation arrangements remain unchanged, and he will not receive any additional compensation for this reclassification.
Solid Biosciences Inc. director Ian F. Smith exercised restricted stock units into common shares. On April 2, 2026 he converted 3,441 restricted stock units into 3,441 shares of common stock at a stated price of $0.00 per share.
The restricted stock units were granted on January 2, 2026 and vest in equal quarterly installments over 12 months from the grant date. Following this transaction, Smith holds 134,705 shares of common stock directly and 10,320 restricted stock units.
Solid Biosciences Inc. is registering up to 42,780,739 shares of its common stock for resale, to be sold from time to time by the selling stockholders named in the prospectus. The registration covers 27,807,482 shares issuable upon exercise of pre-funded warrants issued in the March 2026 private placement.
The prospectus states the company will not receive any proceeds from sales by the selling stockholders. The March 2026 Private Placement closed on March 9, 2026, when the company issued 14,973,257 shares and pre-funded warrants and received gross proceeds of $240.0 million before fees and expenses. Shares outstanding were 98,391,314 as of March 10, 2026.
Solid Biosciences Inc. files a registration statement to register the resale of 1,316,899 shares of its common stock on behalf of selling stockholder FA212 LLC. The shares were issued in private placements under an Asset Purchase Agreement, and the company will receive no proceeds from resales.
The registration covers resale by FA212 LLC of shares issued on January 15, 2026 following dosing in a Phase 1b trial of SGT-212. The prospectus states the selling stockholder may sell shares in public or private transactions, and Solid will bear registration expenses while FA212 LLC will pay sales-related fees.
Solid Biosciences is a gene therapy company focused on rare neuromuscular and cardiac diseases. Its lead program, SGT-003 for Duchenne muscular dystrophy, is in a Phase 1/2 trial with generally well-tolerated dosing in 41 participants and strong microdystrophin expression and biomarker improvements. A global Phase 3 trial in ambulant boys aged 7 to under 12 is starting, with potential accelerated approval discussions planned.
The company is also advancing SGT-212 for Friedreich’s ataxia in a Phase 1b dual-route (brain and IV) study, and SGT-501 for catecholaminergic polymorphic ventricular tachycardia in a Phase 1b trial. Preclinical cardiac candidate SGT-601 targets TNNT2-mediated dilated cardiomyopathy. Solid is building a broad platform around its POLARIS‑101 capsid, next‑generation capsid libraries, and manufacturing partnerships, supported by multiple licenses and collaborations with leading academic centers.
RA Capital Management and affiliates filed Amendment No. 12 to their Schedule 13D on Solid Biosciences Inc., reporting beneficial ownership of 9,313,756 shares of common stock, representing 9.9% of the class. The position includes shares held by RA Capital Healthcare Fund, RA Capital Nexus Fund, a separately managed account, and pre-funded warrants exercisable for up to 8,178,412 shares, subject to a 9.99% beneficial ownership blocker.
In March 2026, the Fund made a series of open-market purchases: 615,259 shares on March 11 at a weighted-average price of $7.28 per share for an aggregate of $4,480,927.77, 302,081 shares on March 12 at $7.66 per share for $2,314,394.77, 691,702 shares on March 13 at $7.32 per share for $5,063,619.06, 1,052,072 shares on March 16 at $7.61 per share for $8,002,475.20, and 493,917 shares on March 17 at $7.79 per share for $3,848,700.05, all funded with the Fund’s working capital.